Related Experiment Videos
Renal cell carcinoma: new prognostic factors?
1Department of Urology, School of Medicine, Dokuz Eylul University, Izmir, Turkey. ziya.kirkali@deu.edu.tr
Current Opinion in Urology
|October 16, 2003
Summary
Predicting survival in renal cell carcinoma (RCC) remains challenging. While new markers are explored, established factors like tumor stage and grade are still the most reliable indicators for patient prognosis.
Area of Science:
- Oncology
- Urology
- Cancer Research
Background:
- Accurate prediction of survival in renal cell carcinoma (RCC) is crucial for treatment planning and clinical trial enrollment.
- Identifying independent prognostic factors aids in selecting patients who may benefit from adjuvant therapies.
Purpose of the Study:
- To review recent developments in identifying prognosticators for patients diagnosed with renal cell carcinoma.
- To highlight the current understanding of factors influencing survival in RCC.
Main Methods:
- Comprehensive literature review of studies investigating prognostic indicators in renal cell carcinoma.
- Evaluation of clinical, histological, molecular, and cytogenetic markers for their predictive value.
Main Results:
- Traditional indicators like tumor stage, grade, and performance status remain significant in predicting RCC outcomes.
- Emerging molecular markers, such as carbonic anhydrase 9, show potential but lack independent validation.
- Advanced staging systems, like the UCLA Integrated Staging System, demonstrate improved survival differentiation compared to traditional staging alone.
Conclusions:
- Despite numerous promising markers identified, none have definitively proven independent prognostic value in renal cell carcinoma.
- Further research is needed to validate novel biomarkers and refine prognostic models for RCC.